跳至主要内容
临床试验/NCT00786305
NCT00786305已完成2 期

Assessment of Efficiency of Nebulized Ceftazidime and Amikacin in Treatment of Ventilator Associated Pneumonia Caused by Pseudomonas Aeruginosa

Groupe Hospitalier Pitie-Salpetriere1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2004年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
40
试验地点
1
主要终点
Bacterial killing

研究概览

简要总结

Pseudomonas aeruginosa is one of the major causative microorganisms of ventilator-associated pneumonia often resistant to antibiotics. In experimental models, nebulization of antibiotics delivers high lung tissue concentrations of antibiotics in infected lungs and increases lung bacterial killing. The aim of the study is to assess the efficiency of nebulized ceftazidime and amikacin in the treatment of pneumonia caused by Pseudomonas aeruginosa in ventilated patients.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Male or female >18 years old, ventilator associated pneumonia caused by pseudomonas aeruginosa
  • Written informed consent provided by the relatives

排除标准

  • Pseudomonas aeruginosa resistant to ceftazidime and amikacin
  • Pseudomonas aeruginosa pneumonia associated with other infections requiring intravenous treatment
  • Severe septic shock and severe hypoxemia
  • Allergy to ceftazidime or amikacin

研究组 & 干预措施

1: nebulized ceftazidime and amikacin

Experimental

干预措施: ceftazidime and amikacin (Drug)

2: intravenous ceftazidime and amikacin

Active Comparator

干预措施: ceftazidime and amikacin (Drug)

结局指标

主要结局

Bacterial killing

时间窗: 14 days

次要结局

  • Changes of lung aeration(8 days)

研究者

发起方
Groupe Hospitalier Pitie-Salpetriere
申办方类型
Other

研究点 (1)

Loading locations...

相似试验